The present invention provides a method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefit in the treatment of cancer, comprising administering an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2-O-methoxyethyl modifications, has nucleotides 5-17 which are 2deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, to a human subject in need of treatment for the cancer, which human subject also receives at least one chemotherapeutic agent, hormone ablation therapy, or radiation therapy, wherein the anti-clusterin oligonucleotide is administered at least 3 times during a 5 to 9 day period, wherein at least 1 of the administrations is at a dose other than 640 mg. The present invention also provides a method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefit in the treatment of myeloma.本發明提供用於提供減少群集素之表現以在癌症治療中提供治療效益之反義療法的方法,其包含向需要針對癌症進行治療之人類個體投與具有序列CAGCAGCAGAGTCTTCATCAT(Seq.ID No.:1)之抗群集素寡核苷酸,其中該抗群集素寡核苷酸具有貫穿始終的硫代磷酸酯主鏈、具有帶有2-O-甲氧乙基修飾之核苷酸1-4及18-21之糖部分、具有為2去氧核苷酸之核苷酸5-17且在核苷酸1、4及19處具有5-甲基胞嘧啶,該人類個體亦接受至少一種化學治療劑、激素消融療法或放射療法,其中該抗群集素寡核苷酸在5至9天時間段期間投與至少3次,其中至少一次投藥劑量不為640mg。本發明亦提供用於提供減少群集素之表現以在骨髓瘤治療中提供治療效益之反義療法的方法。
